Clinical trial
A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor
NCT00187031 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00187031 |
|---|---|
| Title | A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor |
| Official title | A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Collaborators | GlaxoSmithKline Industry National Institutes of Health (NIH) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Wilms Tumor |
| Intervention type | Drug |
| Interventions | Topotecan, Filgrastim (G-CSF), Pegfilgrastim |
| Enrollment | 37 |
| Start date | Nov 1, 2002 |
| Completion | Oct 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Jun 4, 2008 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: